Moolec Science S.A.·Healthcare

WARWICK, GB / ACCESS Newswire / May 14, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the 2026 commercial planting campaign for its GLASO1 safflower program focused on the production of high-GLA ("Gamma-Linolenic Acid") specialty oils for industrial and advanced ingredient applications. "Today represents a defining moment for Moolec.

GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / May 13, 2026 / As previously reported on January 29, 2026, Moolec Science SA ("Moolec" and/or the "Company"), received written notice from the Nasdaq Hearings Panel (the "Panel") informing the Company that the Panel had granted the Company's request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders' equity requirement. The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market's stockholders' equity requirement within the remediation period granted by the Panel.

WARWICK, UK / ACCESS Newswire / April 29, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the first phase of industrialization of its GLASO1 safflower platform, following a 2025 campaign that materially exceeded all internal forecasts. Building on previously reported results confirming approximately 45% GLA ("Gamma-linolenic acid") concentration at commercial scale, the Company has now validated not only agronomic and processing performance, but also the industrial-scale handling and availability of high-purity GLA output, marking a critical step toward full commercial deployment.

WARWICK, GB / ACCESS Newswire / April 7, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced a significant scientific breakthrough in the production of animal proteins in plants. Through a sponsored research project with one of the most prestigious academic institutions in the United States of America, Moolec has successfully demonstrated the stable expression of bovine myoglobin, a heme-containing protein, within the seeds of the common pea (Pisum sativum).

Moolec Science (NASDAQ: MLEC - Get Free Report) is anticipated to release its results before the market opens on Tuesday, April 14th. Analysts expect Moolec Science to post earnings of ($16.50) per share and revenue of $4.3870 million for the quarter. Moolec Science Stock Performance Shares of MLEC stock opened at $11.44 on Tuesday. Moolec Science

Moolec Science (NASDAQ: MLEC - Get Free Report) and Bioceres Crop Solutions (NASDAQ: BIOX - Get Free Report) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Insider and Institutional Ownership 0.1%
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.